Compositions and Methods for the Treatment and Prevention of Antipsychotic Medication-Induced Weight Gain

摘要

The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or dis order based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (AIWG). The methods of the inven tion also provide for different treatments, or different treatment regimens, for the subject depending on the subject's risk of AIWG. Related compositions, in the form of kits, systems, and computer-readable media are also provided.

主权项

1. A method of treating subject in need of treatment with an antipsychotic medication , the method comprising:
(1) determining or receiving the subject's genotype for at least one SNP selected from the group consisting of rs13429709 (SEQ ID NO: 1) (GCG), rs3134701 (SEQ ID NO: 2) (HCRTR2), rs4142972 (SEQ ID NO: 3) (HCRTR2̂2), rs6435326 (SEQ ID NO: 6) (NDUFS1), rs6971 (SEQ ID NO: 9) (TSPO), and rs279858 (SEQ ID NO: 14) (GABRA2); (2) generating a total genetic risk score for the subject by summing a plurality of individual risk scores of the subject, each individual risk score representing the risk of weight gain associated with the subject's genotype for the at least one SNP; (3) generating an AIWG risk assessment for the subject using one or more data attributes including the subject's total genetic risk score; (4) receiving or accessing medication data attributes associating a plurality of medications with the relative tendency of each medication to induce weight gain when administered to a subject; and (5) administering the antipsychotic medication to the subject based on the subject's AIWG risk assessment such that antipsychotic medications having a tendency to induce weight gain are avoided in favor of those having little tendency to induce weight gain where the AIWG risk assessment indicates the subject is at risk for AIWG, thereby minimizing the subject's risk of clinically significant weight gain induced by the medication.